Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RTX-C001
- Development stage
- Unknown
- Lead developer
- Renhaim
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
RTX-C001 is an investigational chimeric antigen receptor T-cell (CAR-T) therapy targeting the B-cell activating factor receptor (BAFF-R). It is being developed for the treatment of lymphoma and potentially other neoplasms, immune system diseases, and hemic and lymphatic diseases. The drug acts as a BAFF-R modulator, aiming to target malignant B cells expressing this receptor. The developer and active organization for this therapy is Renhaim.
- Brand names
- RTX-C001RTX-C-001RTX-C 001
- Other names
- RTX-C001RTX-C-001RTX-C 001
02
Targets
TNFRSF13C (B-cell Activating Factor Receptor)
Beyond the preview
Go deeper on RTX-C001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RTX-C001.